A multicentre retrospective study of the clinical use of @entity25049 in the treatment of XXXX : the ROPI-PARK study.

@entity1 @entity25049 @entity935 @entity344 @entity910 @entity191
OBJECTIVES: To evaluate the use of the non-ergot @entity935 agonist @entity25049 (RPN) in @entity1 with @entity191 in Spain, and to examine its effectiveness and tolerability in both monotherapy and combination therapy. METHODS: Fifty-two investigators participated in this study. @entity1 receiving RPN under usual clinical care conditions in Spanish Neurology outpatient clinic settings were identified (n=643) out of these, a random sample of 423 clinical records of @entity1 treated with RPN in the previous 18 months was selected. The endpoints analyzed were: percentage of @entity1 remaining on treatment during the period of study (maintenance), reported adverse reactions and treatment withdrawal (tolerability), changes in symptoms' severity as assessed by the Clinical Global Impression-Improvement (CGI-I) scale (effectiveness), and start-to-end mean RPN dose. RESULTS: @entity1 were 68.6+/-9.7 years old (mean+/-SD) and 57.6% were male. RPN was administered as monotherapy (24%) or add-on treatment (76%). The mean maintenance dose was 9.54+/-5.34mg/day. Adverse reactions were reported by 28.6% @entity1 , the most frequent being somnolence and sedation (9.2%), @entity344 (6.9%), increase in @entity910 (5.9%), and orthostatic symptoms (3.8%). Treatment was withdrawn in 14.4% of @entity1 , because of adverse reactions (5.9%), lack of efficacy (2.1%), change in treatment or clinical trial inclusion (1.9%) or other reasons (4.5%). Neurologists considered that improvement was achieved in 81.5% of @entity1 , according to CGI-I scale. CONCLUSIONS: The low incidence of adverse reactions and low rate of treatment withdrawal observed in this study support the effectiveness and tolerability of RPN in the treatment of @entity191 .
